Login to Your Account



Clinic Roundup


Friday, August 19, 2011
Cell Therapeutics Inc., of Seattle, opened enrollment for a Phase II trial of Opaxio (paclitaxel poliglumex, or PPX) and radiation in comparison to temozolomide (TMZ) and radiation in glioblastoma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription